Alcohol is renowned for its detrimental impact on the liver, hindering its natural ability to self-heal by disrupting RNA splicing processes. This disruption leads liver cells to linger in a state between functionality and regenerative capacity, even after the cessation of alcohol consumption. A recent study conducted by the University of Illinois Urbana-Champaign, in collaboration with Duke University and the Chan Zuckerberg Biohub Chicago, has shed light on this phenomenon, offering potential treatment avenues by targeting inflammation and restoring ESRP2 levels.
The liver, known for its remarkable regenerative prowess, faces a significant impediment in individuals with alcohol-associated liver disease, a condition responsible for millions of deaths annually worldwide. Even after the termination of alcohol intake, the liver’s regenerative abilities remain compromised. The study spearheaded by biochemistry professor Auinash Kalsotra and Duke University’s professor Anna Mae Diehl sought to unravel the intricacies of this phenomenon, aiming to identify novel therapeutic targets to combat this life-threatening condition.
Over the past five years, the research teams led by Kalsotra and Diehl have delved into the molecular intricacies governing liver regeneration. Their investigations unveiled that liver cells navigate a reprogramming journey to revert to a fetal-like state before transitioning back into fully functional mature cells. Building on this foundation, the researchers delved into the mechanisms that disrupt these regenerative pathways in alcohol-associated liver disease.
By comparing healthy liver samples with those afflicted by alcohol-associated hepatitis or cirrhosis, obtained in collaboration with Johns Hopkins University Hospital, the researchers observed a peculiar phenomenon. Damaged liver cells initiated the transition back to a regenerative state but faltered midway, becoming trapped in an intermediary phase, neither fully functional nor proliferative. This stunted progression towards regeneration contributes to liver failure, elucidating a critical aspect of the disease’s pathology.
Upon scrutinizing the protein production within liver cells and the corresponding RNA molecules dictating this process, the researchers unearthed a pervasive RNA missplicing trend in alcohol-related liver disease. This missplicing, affecting numerous genes and essential protein functions, was attributed to a deficiency of the ESRP2 protein in alcohol-damaged liver cells. ESRP2 plays a vital role in RNA splicing, ensuring the accurate assembly of genetic instructions to form functional proteins within cells.
Further investigations utilizing mice lacking the ESRP2 gene corroborated the pivotal role of this protein in liver damage and regeneration impairment akin to advanced alcohol-related hepatitis in humans. The researchers traced the absence of ESRP2 in alcohol-affected liver cells to the elevated release of inflammatory and growth factors by liver support and immune cells congregating around the alcohol-damaged tissue. These factors suppress ESRP2 production and activity, exacerbating the RNA missplicing and impeding proper liver regeneration.
To validate the potential therapeutic implications of these findings, the researchers treated liver cell cultures with a molecule inhibiting the receptor for an inflammation-promoting factor. This intervention restored ESRP2 levels and rectified splicing activity, hinting at a promising treatment pathway. The potential clinical applications of these discoveries are envisaged to encompass the development of diagnostic markers utilizing misspliced RNAs and the formulation of treatments targeting inflammation to correct splicing defects and enhance liver recovery.
In conclusion, the study’s revelations offer a glimpse into the intricate mechanisms underpinning alcohol-induced liver regeneration impairment. By deciphering the role of RNA splicing disruption and ESRP2 deficiency in this process, the researchers have illuminated potential therapeutic strategies to ameliorate liver damage and restore regenerative capacities. These findings may pave the way for future clinical studies aimed at harnessing the power of RNA splicing modulation and inflammation mitigation to combat alcohol-associated liver disease effectively.
- Alcohol-induced liver damage disrupts RNA splicing, impeding proper liver regeneration.
- ESRP2 deficiency plays a crucial role in RNA missplicing and liver regeneration impairment.
- Inflammatory and growth factors released in alcohol-affected livers suppress ESRP2 production.
- Restoring ESRP2 levels and correcting splicing defects show promise as treatment strategies.
- Targeting inflammation and RNA splicing may offer novel therapeutic avenues for alcohol-associated liver disease.
Read more on scitechdaily.com